Over the 90-day window ending February 19, 2026, Neuphoria Therapeutics's three dominant insider ownership positions are held by TenPercentOwner Capital Management Lp Lynx1 (875.33K shares).
| Holder | Position | Shares | Report Date |
|---|---|---|---|
| Capital Management Lp Lynx1 | 875,328 | 23 Oct, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 21 Oct, 2025 | Capital Management Lp Lynx1 | Common stock, $0.00001 par value per share | A | 639,110 | $5.14 | 875,328 | I | P |